Compare GOSS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOSS | ORIC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.2M | 783.0M |
| IPO Year | 2019 | 2020 |
| Metric | GOSS | ORIC |
|---|---|---|
| Price | $2.51 | $9.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $8.60 | ★ $19.73 |
| AVG Volume (30 Days) | ★ 5.3M | 1.4M |
| Earning Date | 11-05-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,051,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $3.90 |
| 52 Week High | $3.87 | $14.93 |
| Indicator | GOSS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 49.21 |
| Support Level | $2.35 | $7.84 |
| Resistance Level | $3.87 | $8.92 |
| Average True Range (ATR) | 0.27 | 0.40 |
| MACD | -0.12 | 0.19 |
| Stochastic Oscillator | 12.32 | 89.96 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.